Releasing a calcium- and phosphate-containing three-in-one TPN bag

No - hold the bag and reformulate.

The concern is calcium phosphate precipitation, which is the classic fatal TPN incompatibility.

• The commonly applied risk threshold is a calcium × phosphate product (in mmol/L, multiplied) of roughly 72–75. Here 5 × 15 = 75 - at or over the line before any other factor is considered.
• Risk is pushed higher by: temperature (it will sit at room temperature for 24 hours), pH (dibasic phosphate salts raise pH, and the fraction of divalent phosphate increases, binding more calcium), order of mixing and local concentration at the injection port, and the lipid emulsion, which can mask a precipitate so visual inspection cannot exclude it.
• Potassium load: 30 mmol of phosphate given as potassium phosphate supplies roughly 40–45 mmol of potassium. Check the serum potassium and the daily potassium target before release - this alone may require reformulation.

Practical resolution, in order of preference:

1. Reduce the phosphate and/or calcium to bring the product comfortably below the threshold, keeping the bag's final volume unchanged.
2. Switch to sodium phosphate if the potassium load is the limiting factor.
3. Divide calcium and phosphate between bags, or use a 2-in-1 with calcium and a separate lipid, so they never share the same compartment.
4. Always add phosphate first, calcium last, with agitation between additions, and only within a validated compatibility range - do not extrapolate 'it looked fine last time'.

Use a 1.2 micrometre filter for a lipid-containing admixture and 0.22 micrometre for a 2-in-1; a filter is a safety net, not permission to release an over-saturated bag.

Release checks (in order):

1. Order verification and calculation check by a second person: dextrose and amino acid amounts, kcal and nitrogen, osmolarity and suitability for central administration, electrolyte totals including potassium and sodium, and vitamin/trace element compatibility.
2. Sterility assurance: aseptic technique record, environmental monitoring and media-fill results current; the person preparing and the person checking both sign.
3. Visual inspection against a light and dark background for phase separation, creaming, oil droplets, discolouration and particulates - documented, but explicitly understood as insufficient to exclude micro-precipitation.
4. Label with full contents, total volume, flow rate, storage conditions and exact expiry date/time.

Beyond-use date reasoning:

• This is not a single-additive, single-transfer preparation; it is a multi-additive compounded admixture, which places it in a higher risk category. Assign the BUD according to the current USP <797> category criteria and the equivalent DHA-aligned local policy in force at your site rather than from memory of an older edition - the categories and limits have been revised.
• Because the bag hangs for 24 hours at room temperature, the in-use expiry coincides with the end of the infusion, so the compounded BUD must be at least that long and must be dated from the start of preparation, not from hanging.
• For a 5-day course, prepare a fresh bag daily rather than storing one bag for 5 days; do not use a single bag across multiple days.
• Store refrigerated (2–8 °C) before use, protect from light with the vitamin mix, and allow equilibration to room temperature before hanging.
• Document the intervention, the reformulation discussion with the prescriber and the final approved formula.